Review article: The reversibility of cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 9, 2012, Pages 824-832

  Sohrabpour, A A ^a   Mohamadnejad, M ^a   Malekzadeh, R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; INTERSTITIAL COLLAGENASE; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; ELASTOGRAPHY; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RELAPSE; REVIEW; VIRUS REPLICATION;

DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX;

EID: 84878526074     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12044     Document Type: Review

References (101)

1. Ganji A, Malekzadeh F, Safavi M, et al. Digestive and Liver Disease Statistics in Iran. Middle East J Dig Dis 2011; 1: 56-62.
2. Abedian S, Soleimani H, Saberifiroozi M, Malekzadeh R. Common Digestive and Liver Diseases among 5880 Patients Admitted to Shariati Hospital, Tehran, Iran during 2000-2009. Middle East J Dig Dis 2011; 1: 56-62.
3. Sohrabpour AA, Rezvan H, Amini-Kafiabad S, Dayhim MR, Merat S, Pourshams A. Prevalence of nonalcoholic steatohepatitis in Iran: a population based study. Middle East J Dig Dis 2010; 2: 14-9.
4. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18. (Pubitemid 40385459)
6. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69. (Pubitemid 351615417)
7. Dranoff JA, Wells RG. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010; 51: 1438-44.
8. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008; 233: 109-22. (Pubitemid 351231543)
9. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology 2009; 50: 2007-13.
10. Bioulac-Sage P, Lafon ME, Saric J, Balabaud C. Nerves and perisinusoidal cells in human liver. J Hepatol 1990; 10: 105-12. (Pubitemid 20006996)
11. Bonacchi A, Petrai I, Defranco RM, et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003; 125: 1060-76. (Pubitemid 37193453)
12. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42(Suppl): S22-36. (Pubitemid 40364601)
13. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503. (Pubitemid 36258768)
14. Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med 2001; 344: 495-500. (Pubitemid 32164902)
15. Merat S, Sotoudehmanesh R, Nouraie M, et al. Sampling error in histopathology findings of nonalcoholic Fatty liver disease: a post mortem liver histology study. Arch Iran Med 2012; 15: 418-21.
16. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5. (Pubitemid 16138427)
17. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64. (Pubitemid 40165369)
18. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417.
19. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-35.
20. Montazeri G, Estakhri A, Mohamadnejad M, et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005; 5: 32.
21. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13. (Pubitemid 39575849)
22. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49: 450-4. (Pubitemid 36250205)
23. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology 2004; 127: 1847-9. (Pubitemid 39575865)
24. Sandrin L, Cassereau D, Fink M. The role of the coupling term in transient elastography. J Acoust Soc Am 2004; 115: 73-83. (Pubitemid 38112408)
25. Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: fibroscan: an acceptable alternative for liver biopsy. Hepat Mon 2011; 11: 157-8.
26. Boursier J, Konate A, Guilluy M, et al. Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. Eur J Gastroenterol Hepatol 2008; 20: 693-701.
27. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73. (Pubitemid 46999083)
28. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47: 332-42. (Pubitemid 351171070)
29. Faria SC, Ganesan K, Mwangi I, et al. MR imaging of liver fibrosis: current state of the art. Radiographics 2009; 29: 1615-35.
30. Walewska-Zielecka B, Madalinski K, Jablonska J, Godzik P, Cielecka-Kuszyk J, Litwinska B. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression. World J Gastroenterol 2008; 14: 4040-6.
31. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-80. (Pubitemid 30227116)
32. Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology 2009; 49: S61-71.
33. Ruiz-Moreno M, Otero M, Millan A, et al. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29: 572-5. (Pubitemid 29088464)
34. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
35. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003; 348: 808-16. (Pubitemid 36245757)
36. Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-55. (Pubitemid 34717666)
37. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003; 348: 800-7. (Pubitemid 36245756)
38. Malekzadeh R, Mohamadnejad M, Rakhshani N, et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 344-7. (Pubitemid 38447201)
39. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7. (Pubitemid 30485234)
40. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 2004; 351: 1521-31.
41. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17. (Pubitemid 36055344)
42. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999; 341: 1256-63. (Pubitemid 29489740)
43. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42: 173-9. (Pubitemid 40143462)
44. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. New Engl J Med 2007; 357: 2576-88. (Pubitemid 350294224)
45. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med 2006; 354: 1011-20. (Pubitemid 43357805)
46. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl J Med 2006; 354: 1001-10. (Pubitemid 43357804)
47. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
48. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-6.
49. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory. HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49. (Pubitemid 43816960)
50. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51. (Pubitemid 44958517)
51. Histologic Improvements Associated with Long-Term Treatment with Tenofovir for Chronic HBV Infection. 2011. Available at: http://www.hopkinscme. net/ofp/eViralHepatitisReview/newsletters/2011/1211.html. Accessed August 19, 2012.
52. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
53. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35: 107-12. (Pubitemid 38133930)
54. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
55. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-8. (Pubitemid 39265275)
56. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24. (Pubitemid 30171890)
57. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42. (Pubitemid 38222174)
58. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13. (Pubitemid 34465173)
59. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
60. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.
61. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
62. Garber K. Hepatitis C: move over interferon. Nat Biotechnol 2011; 29: 963-6.
63. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-51. (Pubitemid 40543746)
64. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-5. (Pubitemid 27516609)
65. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-30. (Pubitemid 32378277)
66. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52. (Pubitemid 38367787)
67. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, et al. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med 2004; 117: 125-9. (Pubitemid 38953734)
68. Malekzadeh Z, Haghazali S, Sepanlou SG, et al. Clinical features and long term outcome of 102 treated autoimmune hepatitis patients. Hepat Mon 2012; 12: 92-9.
69. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007; 11: 75-104, ix. (Pubitemid 46829977)
70. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33: 284-6.
71. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
72. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Engl J Med 2006; 355: 2297-307. (Pubitemid 44837778)
73. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010; 362: 1675-85.
74. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104: 23-31.
75. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
76. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005; 9: 135-49. (Pubitemid 40341950)
77. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006; 37: 1519-26. (Pubitemid 44792230)
78. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-7. (Pubitemid 44214887)
79. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 425-36.
80. Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 2012; 109: 9448-53.
81. Subeq YM, Ke CY, Lin NT, Lee CJ, Chiu YH, Hsu BG. Valsartan decreases TGF-beta1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats. Cytokine 2011; 53: 223-30.
82. Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011; 55: 612-25.
83. Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 2011; 25: 305-17.
84. Yang L, Bataller R, Dulyx J, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005; 43: 317-23. (Pubitemid 40956886)
85. Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-72.
86. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32. (Pubitemid 350073596)
87. Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1318-28. (Pubitemid 43788315)
88. Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-54. (Pubitemid 37026470)
89. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-26.
90. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-21. (Pubitemid 43668827)
91. Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 2005; 11: 3431-40. (Pubitemid 40873250)
92. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40: 1304-11. (Pubitemid 39657004)
93. Zhao W, Li JJ, Cao DY, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 2012; 18: 1048-58.
94. Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 2008; 135: 438-50.
95. Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011; 54: 820-8.
96. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-66. (Pubitemid 350001896)
97. Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 2007; 13: 3359-63. (Pubitemid 47062247)
98. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-6. (Pubitemid 43865236)
99. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009; 31: 145-53.
100. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 2005; 43: 499-507. (Pubitemid 41111433)
101. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-17.